The Clinical Values of Serum Markers in the Early Prediction of Hepatocellular Carcinoma
Table 3
Analysis of risk factors for the development of HCC based on the levels of serum tumor markers.
Markers
HCC ()
Non-HCC ()
Cumulative incidence (CI)
Relative Risk (RR)
Attributable Risk (AR)
Attributable Risk Percent (ARP)
Chi-Square
Value
ALB (g/l)
Positive groups
23
54
29.87%
1.06
1.75%
5.84%
0.033
0.855
Negative groups
9
23
28.13%
TBIL (μmol/L)
Positive groups
21
44
32.31%
1.09
2.76%
8.55%
0.093
0.760
Negative groups
13
31
29.55%
ALT (U/L)
Positive groups
24
30
44.44%
2.72
28.08%
63.18%
10.178
0.001
Negative groups
9
46
16.36%
PLT (109/L)
Positive groups
27
59
31.40%
1.20
5.31%
16.91%
0.242
0.623
Negative groups
6
17
26.09%
PT(s) (s)
Positive groups
20
49
28.99%
0.97
−1.01%
−3.50%
0.013
0.911
Negative groups
12
28
30.00%
PT(a) (%)
Positive groups
17
52
28.81%
0.77
−8.69%
−30.15%
2.020
0.155
Negative groups
15
25
37.50%
AFP (ng/mL)
Positive groups
24
25
48.98%
2.99
32.59%
66.53%
13.511
0.000
Negative groups
10
51
16.39%
GP73 (ng/mL)
Positive groups
27
64
29.67%
0.89
−3.66%
−12.35%
0.096
0.757
Negative groups
6
12
33.33%
AFP-L3 (ng/mL)
Positive groups
22
20
52.38%
2.92
34.47%
65.81%
14.292
0.000
Negative groups
12
55
17.91%
L3/AFP ratio
Positive groups
18
19
48.65%
2.34
27.82%
57.18%
8.958
0.003
Negative groups
15
57
20.83%
HCC: patients who had developed HCC during the study period; non-HCC: patients who had not developed HCC during the study period; : number of patients.
